Alberto Mussetti

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis Key PointsReal-world effectiveness and safety outcomes in patients with R/R MCL treated with brexu-cel are similar to those of the ZUMA-2 trial.The benefit

Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis url: ashpublications.org/bloodadvance...

Microenvironmental regulation of solid tumour resistance to CAR T cell therapy - Nature Reviews Immunology The tumour microenvironment (TME) poses a significant obstacle to the success of chimeric antigen receptor (CAR) T cell immunotherapy in solid tumours. Here, the authors detail how both cellular and n...

www.nature.com/articles/s41...

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy Background Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). ...

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy jitc.bmj.com/content/13/1...

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023

24th OCT 2025 - Barcelona

Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.

#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution

lnkd.in/dBDXnaSK

In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | NEJM In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi...

mRNA for CART manufacturing for LES...

www.nejm.org/doi/full/10....

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT Key PointsAugmented CD47 expression on alloreactive donor T cells after HCT inhibits their phagocytosis by macrophages.Anti-CD47 treatment boosts phagocyto

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...

Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies Key PointsWU-CART-007, an allogeneic anti-CD7 chimeric antigen receptor T cell, established a manageable safety profile at the RP2D of 900 × 106 cells.WU-C

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...

A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept Key PointsPTCy+Aba arm is associated with less chronic GVHD and a favorable GRFS compared with methotrexate/tacrolimus.PTCy and Aba without a calcineurin i

ashpublications.org/bloodadvance...

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma Key PointsDespite similar CAR T-cell dynamics, patients with SLE experienced less severe adverse events after CAR T-cell therapy than those with B-NHL.In p

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...

Lymphoma accelerates T cell and tissue aging Hesterberg et al. show that lymphoma provokes marked and rapid changes in young T cells that recapitulate the transcriptional, epigenetic, and senescent features manifest in aged T cells, including ag...

www.cell.com/cancer-cell/...

Novel tool helps identify key targets to strengthen CAR NK cell therapies Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research...

www.mdanderson.org/newsroom/nov...

What Does It Take to Get Men to See a Doctor?

www.nytimes.com/2025/08/25/m...

Educational Strategies for Clinical Supervision of Artificial Intelligence Use | NEJM Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors provide an approach to clinical supervision that can mitigate the perils and ...

www.nejm.org/doi/full/10....

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy | NEJM A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...

www.nejm.org/doi/full/10....

Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy Zelig Eshhar, PhD, Fellow of the Academy of Immuno-Oncology (FAIO), passed away on July 3, 2025, at the age of 84. His passing is deeply personal to all of us and for the entire field of cancer immuno...

jitc.bmj.com/content/13/8...

Que la IA et diagnostiqui: el ChatGPT que ja fa servir el teu metge L'eina estarà a prova aquest any per donar suport als professionals sanitaris en la presa de decisions

www.ara.cat/1_535642

Opinion | You Are Contaminated

www.nytimes.com/2025/08/04/o...

Could Dementia Patients Benefit from an A.I. Companion?

www.nytimes.com/2025/07/31/w...

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability Key PointsUnique molecular features of Super-class HSCs were identified through analyses of single-clone serial transplants.Low expression of CD27 is a key

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability url: ashpublications.org/blood/articl...

Dear friends and colleagues,

We would love to have you join this year’s Transplant Complications Working Party Educational Meeting in Dubrovnik, Croatia, on the 1st-3rd of October. The EBMT

More information here:

www.ebmt.org/events/trans...

We look forward to seeing you in Dubrovnik!

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Key PointsLS, an emergent form of acute leukemia relapse after antigen-targeted therapy, primarily in B-ALL, has dismal outcomes.LS arises rapidly after im

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia url: ashpublications.org/blood/articl...

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study Key PointsProphylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy.Prophy

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study url: ashpublications.org/blood/articl...

Clonal hematopoiesis and risk of non-myeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation AbstractPurpose. Examine the association between clonal hematopoiesis (CH) and non-myeloid subsequent malignant neoplasms (SMNs) after autologous hematopoi

academic.oup.com/jnci/advance...

Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma Key PointsLargest real-world study of ide-cel in R/R MM shows favorable safety and efficacy profile that mirrors trial experience.Significant comorbidities

ashpublications.org/blood/articl...

Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma Key PointsAntigen-negative escape is a key driver of relapse after GPRC5D CAR T-cell therapy in MM.Homozygous deletion and hypermethylation of GPRC5D are i

ashpublications.org/blood/articl...

Antibiotic use: impact on the microbiome and cellular therapy outcomes Abstract. Antibiotics disrupt the delicate balance of bacteria, fungi, and viruses in the human microbiome. Growing evidence indicates a significant relati

ashpublications.org/bloodadvance...

Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies - Blood Cancer Journal Blood Cancer Journal - Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

www.nature.com/articles/s41...

Virtual twins for personalised CAR T-cell therapy in myeloma Multiple myeloma is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. Despite advances in treatment, multiple myeloma remains incurable, with mo...

www.thelancet.com/journals/lan...